InterVenn Investigator Initiated Research Program in Glycoproteomics

News

May 6, 2022 - InterVenn to Present New Clinical Data at ASCO 2022
Read more

May 5, 2022 - Bank of America 2022 Healthcare Conference, May 10, 2022 at 2:00pm PT / 5:00pm ET
Click here for webcast

April 7, 2022 - InterVenn to Showcase Novel Translational Research Opportunities Based on Glycoproteomics at AACR 2022Read more

March 24, 2022 - Veteran Healthcare Executive and Reimbursement Expert Joins InterVenn Biosciences’ Board of AdvisorsRead more

January 24, 2022 - InterVenn Promotes Klaus Lindpaintner to InterVenn Distinguished Scientist; Appoints Tillman Pearce as Chief Medical OfficerRead more

January 6, 2022 - InterVenn Biosciences, the leader in glycoproteomics, today announced that it has named Brian Hogan as Chief Financial Officer.Read more

Company Events and Presentations

March 4, 2022 - Cowen 42nd Annual Health Care Conference, March 7, 2022 at 12:50 PM ET / 9:50 AM PT
Click here for webcast

January 5, 2022 - InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST.
Read more

November 11, 2021 - InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences

A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.

Investors